ClinicalTrials.gg

Program

Meropenem

Also written as “meropenem” and “Meropenem plus vaborbactam”.

Its studies are mostly in Sepsis · Enterocolitis, Necrotizing · Bacterial Infections · Pancreatitis · Cellulitis, led by 2 companies.

Furthest: phase 4, since May 27, 20035 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer40 open or runningphase 4since May 27, 2003May 27, 2003none ahead
The Emmes10 open or runningphase 2since Feb 20, 2008Feb 20, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2003First study: phase 4 study in Pancreatitis, Acute NecrotizingNew to PfizerPfizer · NCT00061438 · 240 enrolled · United States, Canada
  2. Apr 25, 20062 phase 4 studiesPfizer · NCT00318552, NCT00318994
  3. Feb 6, 2008Phase 3 study in CellulitisPfizer · NCT00619710 · 1,000 enrolled
  4. Feb 20, 2008The Emmes's first study: phase 2 study in Enterocolitis, NecrotizingNew to The EmmesThe Emmes · NCT00621192 · 200 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial penicillin-binding protein inhibitor”ChEMBL 37, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT00621192Enterocolitis, Necrotizing · United States2CompletedThe EmmesOct 2009200
NCT00619710Cellulitis3CompletedPfizerDec 20031,000
NCT00318994Pancreatitis · Colombia4CompletedPfizerSep 20056
NCT00318552Sepsis · Hungary4CompletedPfizerJun 2006160
NCT00061438Pancreatitis, Acute Necrotizing · United States, Canada4CompletedPfizerDec 2004240

How it is read

Names in the registry

  • “Meropenem”, 6 entries
  • “meropenem”, 3 entries
  • “Meropenem plus vaborbactam”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.